vijaya bpc 157 Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing BPC-157 – Mark Hyman, MD

(PubMed) Maruti SS, Ulrich CM, White E

When switching from oral to injectable, reduce your dose by approximately 50-60% initially and adjust based on response

They are a huge part of our revenue and referrals

Cagrilintide, the second generation (2020s) Novo Nordisk took the Pramlintide concept and applied the same half-life extension strategy that they used with Semaglutide: Kept the proline substitutions (anti-amyloid) Added a C20 fatty diacid via a -Glu linker to a lysine residue, albumin binding Additionally stabilized the N- and C-terminal positions Result: Cagrilintide with a half-life of 6.6 days (vs 50 minutes for Pramlintide)

The secret is a simple but powerful solution

doi: 10.1038/ki.2011.179